Does Somatostatin Interact with Copper Cu 64 Dotatate?
Somatostatin and Copper Cu 64 Dotatate have a moderate drug interaction according to U.S. FDA drug labeling data. Short-acting somatostatin analogs competitively bind to somatostatin receptors (SSTR2), affecting imaging. A washout period of 2 days is recommended prior to imaging. The mechanism involves competitive binding to somatostatin receptors (sstr2). Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Copper Cu 64 Dotatate Class
- Radioactive Diagnostic Agent
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Somatostatin and Copper Cu 64 Dotatate occurs because competitive binding to somatostatin receptors (sstr2). Clinically, this means short-acting somatostatin analogs competitively bind to somatostatin receptors (sstr2), affecting imaging. a washout period of 2 days is recommended prior to imaging. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Somatostatin and your doctor is considering prescribing Copper Cu 64 Dotatate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider